Introduction
The physical structure of virions and the replicative cycle of HIV-1 provide many potential targets for gene therapy. To date, several RNA and protein agents have been introduced into susceptible cells and tested as inhibitors of HIV-1 replication. These studies have included dominant negative mutants of HIV structural (Gag, 1 Env 2 ) or regulatory (Rev, 3 Tat, 4 PR 5 ) proteins, TAR 6 and RRE 7 RNA decoys molecules for the viral proteins (Tat, REV), antisense RNAs, 8 antibodies directed against Rev, 9 gp120 10 or Tat, 11 and ribozyme designed to cleave at different conserved sites of the HIV-1 genome. 12, 13 These approaches all target phases of HIV-1 replication before virus assembly. Alternatively, gp160 proteolytic processing can be inhibited after expression of an ER-retained CD4 chimera in primary human T cells. 14 We describe here a different approach to anti-HIV genetic therapy, one that inhibits proteolytic processing of HIV-1 capsid and envelope proteins necessary in the HIV late replicative cycle. HIV envelope glycoproteins control viral tropism and promote membrane fusion. They are synthesized as inactive 160 kDa precursors, 15 and activated by endoproteolytic cleavage at the carboxyl terminus of the basic consensus sequence Arg-X-Lys/ Arg-Arg. 16, 17 This sequence is recognized by the kexin/ subtilisin-like serine proteases. 18 The cellular serine protease, furin, was the first of this group that was shown to catalyze proteolytic maturation of both HIV-1 and influenza virus envelope glycoproteins. 19 Recent data suggest that other proteases may also be involved in such processing (for review see Ref 20) .
HIV-1 protease (PR) is an aspartyl protease that is needed to process the gag precursor polyprotein into several smaller proteolysis products. 21 Just as cellular serine protease activity is fundamentally important to envelope, viral aspartyl protease activity is required for gag proprotein processing: both processes are necessary to generate infectious viral progeny. 19, 22 Thus, gene delivery to inhibit proteolytic cleavage of envelope and gag precursors could represent a new approach for gene therapy to interfere with HIV-1 infectivity.
In the present work, we evaluated the ability of a native human protein, a 1 antitrypsin (a 1 AT), to block maturation of HIV-1 proproteins. a 1 AT, a 53 kDa serum protein is the main physiologic inhibitor of neutrophil elastase and other enzymes. 23 a 1 AT thus controls proteolysis associated with tissue injury and represents an important modulatory defense against proteolytic tissue damage.
We have developed a gene transfer system based on simian virus-40 (SV40) as a vector. 24 SV40 infects a wide range of cell types from human and other mammals, ensuring the expression of its genome. Recombinant, T-antigen deleted, replication-deficient, SV40-derived vectors deliver stable transgene expression with high efficiency and without selection to cell lines and in primary cell cultures, and in vivo. [24] [25] [26] rSV40 vectors can be concentrated to high titer (410 12 infectious units (IU)/ml), stably integrate into the host genome, do not require helper viruses, and do not elicit cellular or humoral responses in animals. 27 We delivered native human a 1 AT, a protease inhibitor, to human lymphocyte cell lines and primary human lymphocyte cultures using an rSV40-based vector (SV(AT)). We demonstrate that SV(AT) strongly inhibits replication and spread of HIV-1 by blocking two necessary steps in HIV-1 proprotein processing: it blocks cellular serine proteases that are involved in processing of gp160 to gp120 and gp41, and, surprisingly, it also decreases the activity of HIV-1 PR, an aspartyl protease that cleaves p55
Gag within the budding viral particles.
Results
Detection of a 1 AT in lymphocytic cells transduced with SV(AT)
Prior to examining the ability of a 1 AT to alter HIV-1 replication in T cell lines and peripheral blood lymphocytes (PBL), we assessed the ability of SV(AT) to transduce these cells. Thus, SupT1 cells and normal primary human PBL were transduced as described in Materials and methods with SV(AT). In our experience, the rSV40 treatment protocol used routinely transduces 495% of these cells, without selection. 28 Transduction of these cells with SV(HBS) was used as a negative control; mock-transduced HepG2 cells, expressing high levels of endogenous a 1 AT, were used as a positive control. Samples of 15 mg of total cell RNA were electrophoresed, blotted and hybridized with a human a 1 AT-specific cDNA probe. Expression of human a 1 AT was seen in SV(AT)-transduced cells but not in mock-transduced cells, or in SV(HBS)-transduced cells (Figure 1a) . A 1.3 kb transcript, observed in the SV(AT)-transduced cells, corresponds in size to the native a1-AT detected in the positive control cell line, HepG2. In addition, we found that a1-AT protein was easily detected after immunoprecipitation of total cell proteins from SV(AT)-transduced SupT1 cells (Figure 1b) . To illustrate the transduction efficiency of SV(AT) vector in HIV-1-susceptible cells, SupT1 cells were transduced with SV(AT), or SV(HBS) as a negative control. Unselected cells were tested for AT expression by immunofluorescence microscopy 2 weeks later. Over 98% of SV(AT)-treated cells expressed a 1 AT (Figure 2a ). Control cells transduced with SV(HBS) did not express a 1 AT. The growth and viability of transduced cells were unaltered by transduction, as assayed by counting of trypan-bluenegative cells (Figure 2b ).
Inhibition of HIV-1 by a 1 AT in human T-lymphocytic cell lines
We then tested whether expression of a 1 AT delivered by SV40 to SupT1 cells could prevent HIV-1 NL4-3 cytotoxicity and replication in this line of susceptible human Tlymphoid cells. Mock-transduced SupT1 cells alone and unselected cells expressing a 1 AT or HBsAg were used for infectivity assay. For HIV-1 challenge experiments, unselected a 1 AT-transduced SupT1 cells, SV(HBS)-transduced SupT1 cells and mock-transduced SupT1 cells were treated with different amounts of HIV-1 NL4-3 .
Inhibition of HIV-1-induced cytopathic effects by a 1 AT Microscopically, SV(AT)-transduced SupT1 cells showed no evidence of HIV-1-related cytopathic effects when challenged with HIV-1 NL4-3 ( Figure 3 ). That is, HIVinduced syncytia and cell death were not seen. On day 18 after challenge, mock-transduced SupT1 cells or SV(HBS)-transduced SupT1 cells started to die. By comparison, SupT1 cells transduced with a 1 AT continue to proliferate normally. Thus, a 1 AT expression protected cells against the cytopathic effects of HIV-1.
Inhibition of HIV-1 replication by a 1 AT
Replication of HIV-1 in these cultures was evaluated by measuring levels of HIV-1 p24 antigen released into the culture medium. HIV-1 p24 analyses demonstrated that a 1 AT conferred protection from infection at challenge doses of 4000 and 40 000 TCID 50 of HIV-1 NL4-3 (0.004 and 0.04 MOI of HIV-1 NL4-3 , respectively) whereas cells expressing HBsAg and mock-transduced SupT1 cells permitted high levels of HIV-1 p24 replication ( Figures  4a and b) . a 1 AT inhibition of HIV-1 in primary human cell cultures Successful transduction and protection from HIV-1 in susceptible primary human cells is essential for gene therapy to be practicable. The higher the levels of transduction and protection, the more likely that this (Figures 4c and d) . That is, gp160 was efficiently cleaved intracellularly to yield gp120 in SupT1 cells expressing HBsAg. On the other hand, gp160 was the predominant envelope glycoprotein molecular species detected in SV(AT)-transduced SupT1 cells: its processing to gp120 was efficiently inhibited by transduction with SV(AT).
To confirm the inhibitory effect of a 1 AT on HIV-1 envelope glycoprotein processing in primary cell cultures, SV(AT)-transduced and SV(BUGT)-transduced PBL were treated with 10 000 TCID 50 (0.01 MOI) of HIV-1 NL4-3 . Cells were lysed 7 days later. Inhibition of gp160 conversion to gp120 by SV(AT) was also seen in processing. These findings were confirmed by studying gp120 content of virus particle progeny from SV(AT)-transduced cells. For this purpose, unselected and uncloned SV(AT)-transduced and SV(HBS)-transduced SupT1 cells were treated with 10 000 TCID 50 (0.01 MOI) of HIV-1 NL4-3 . Cell-free culture supernatants were harvested 7 days post-challenge, and subjected to ultracentrifugation for virion purification as described in Materials and methods.
gp120 was the sole envelope species detectable present in virus particle progeny recovered from SV(HBS)-transduced cells, but no gp120 was detected in virus progeny from SV(AT)-transduced SupT1 cells ( Figure 6 , left panel). The latter virus particles only carried the uncleaved envelope glycoprotein gp160 detectably. These findings were confirmed after infection of SV(AT)-transduced and SV(BUGT)-transduced PBL with 40 000 TCID 50 (0.04 MOI) of HIV-1 NL4-3 . Cell culture supernatants were harvested at day 7 post-infection and subjected to ultracentrifugation for virion purification as described in Material and methods. Analyses by Western blot for envelope glycoprotein ( Figure 6 , right panel) confirmed the findings with SupT1 cells: gp160 was the predominant envelope glycoprotein molecular species detected in SV(AT)-transduced PBL virus particle progeny.
Inhibition of gp160 cleavage should also result in decreased gp41, in both virions and cells. Therefore, 10 6 SupT1 cells were transduced with SV(AT) or SV(HBS), 6 mock-transduced PBL and PBL transduced with SV(AT) or SV(BUGT) were challenged with 4000 (c) or 40 000 (d) TCID 50 of HIV-1 NL4-3 . HIV-1 replication was quantitated by assaying HIV-1 p24 antigen levels in the culture supernatants by ELISA at the time points indicated after challenge. These graphs are representative of three independent experiments. Performing the Student t-test on individual data points indicated statistically significant differences (Po0.01) in p24 levels between SV(AT) transduced and all control groups for assay points 12 days post-challenge.
Inhibiting HIV-1 proprotein processing P Cordelier et al then challenged with 10 000 TCID 50 HIV-1. After 7 days of culture, HIV virions were purified from culture supernatants, and proteins were prepared from these virions and the transduced cells that produced them.
Western blot analysis of these protein preparations revealed decreased gp41 ( Figure Inhibiting HIV-1 proprotein processing P Cordelier et al with 10 000 TCID 50 (0.01 MOI) of HIV-1 NL4-3 . Cell-free culture supernatants were harvested at day 7 postchallenge, and subjected to ultracentrifugation for virion purification as described in Materials and methods. Equal amounts of total viral protein were separated by SDS-PAGE and analyzed by Western blotting. High levels of uncleaved p55 Gag protein were detected in virus particle progeny recovered from cells expressing a 1 AT, compared to SV(HBS)-transduced SupT1 cells (Figure 9 , upper left panel). Moreover, conversion of p55
Gag into virion p24 was strongly inhibited in SV(AT)-transduced cells, compared to SV(HBS)-transduced cells. Western blot analysis using a specific HIV-1 p24 antibody showed that high levels of HIV-1 p24 were only detectable in virions recovered from SV(HBS)-transduced SupT1 cells, but not in those recovered from cultures of SV(AT)-transduced cells (Figure 9 , lower left panel). These results were confirmed by Western blot analyses of virus particle progeny from PBL expressing a 1 AT (Figure 9 , right panel). These data strongly suggest that, whether directly or indirectly, a 1 AT inhibits the activity of the HIV-1 PR, an aspartyl protease.
Discussion a 1 AT is a member of the superfamily of inhibitors referred to as serpin (serine protease inhibitor). a 1 AT is produced and exported by the liver, is found in its active form primarily in the plasma, and accounts for more than 1% of plasma mass (for review see Ref 23) . The primarily function of this serpin is to regulate the remodeling of the extracellular matrix: to achieve this goal, a 1 AT neutralizes neutrophil elastase activity by acting as a suicide substrate for the target protease. 29 Protease inactivation by a 1 AT results from the formation of a highly specific stable adduct between the active site serine of elastase and the residue Met358 in the serpin. 30 To be infectious, HIV-1 virus requires viral glycoprotein maturation by host cell proteins, probably by endoproteases in the Golgi apparatus. Env proprotein is organized as a trimer, and envelope structures are derived from a gp160 kDa precursor, gp160, which is cleaved into a gp120 external surface envelope species and gp41, a transmembrane glycoprotein. 16 The virion gp120, located at the virus surface, interacts with lymphocyte CD4 receptor to initiate the entry of HIV-1 into CD4-postive cells. 31 . Expression of gp160 in different mammalian cell types and in yeast demonstrated that the intracellular gp160-processing activities are ubiquitously expressed. 32 Mammalian convertases such as furin cleave the envelope precursors. 19 Based on these observations, the catalytic site of a 1 AT was exchanged with the consensus sequence recognized by convertases. The engineered serpin (a 1 AT Portland, a 1 PDX) was shown to be a potent inhibitor of furin.
33,34 a 1 PDX was shown to block the processing of HIV-1 gp160 in transfected cells, and the activity of furin, as well as other proteases. Recently, a 1 PDX has been reported to interfere with HIV-1 replication, after stable transfection in the CD4-positive Jurkat cells. 35 Inhibition of the cytopathic effect of HIV-1 and of virus replication appeared to correlate with the capacity of the engineered serpin to interfere with the maturation of gp160 to gp120 and gp41. Recently, a 1 AT has been reported as a candidate circulating HIV-1 inhibitor in vivo. Inhibiting HIV-1 proprotein processing P Cordelier et al
Here, we report that native human a 1 AT delivered by an rSV40 vector strongly inhibits HIV-1 replication in vitro. We observed that a 1 AT expression after SV(AT) transduction protected cells against the cytopathic effects of HIV-1. The results of HIV-1 p24 analysis demonstrated that a 1 AT conferred protection to SupT1 cells from HIV-1 NL4-3 challenge doses of 4000 and 40 000 TCID 50 (0.004 and 0.04 MOI, respectively), whereas cells expressing HBsAg and mock-transduced SupT1 permitted high levels of HIV-1 replication at these doses. Further confirmation was obtained by demonstrating that SV(AT) effectively transduced and protected unstimulated human PBL. For comparison, the single-chain Fv (SFv) antibody IN #33 against HIV-1 integrase delivered by both rSV40 and retroviral vectors was highly effective in inhibiting HIV-1 replication at challenge doses of 40 TCID 50 , but its protective efficiency was less evident at higher challenge doses: it did not alter the course of HIV-1 infection at challenge doses of 400 TCID 50 . 28 We have yet to identify a challenge dose of HIV-1 that can completely overwhelm the protective effect of a 1 AT. Preliminary experiments showed a 60% reduction of HIV-1 replication in SupT1 cells transduced with SV(AT) challenged with 0.3 MOI of HIV-1 NL4-3 , compared to control cultures (data not shown).
The strength of the protective effect of a 1 AT may rest in the fact that its principal target is cellular, not viral, protein. Increasing the HIV viral challenge dose is unlikely to compensate for a block in cellular proteinin this case serine protease -activity. We hypothesized that the serpin a 1 AT would interfere with HIV-1 replication by blocking endoproteolytic activation of gp160. Western blot analyses showed that gp160 was the predominant molecular species envelope glycoprotein detected in SV(AT)-transduced Supt1 cells and primary human lymphocytes: its processing to gp120 was efficiently inhibited by transduction with SV(AT). Furthermore, HIV virus particles recovered from SV(AT)-transduced SupT1 cells and primary human lymphocytes only contained the uncleaved envelope glycoprotein gp160 detectably. Taken together, these results showed that a 1 AT delivered by SV(AT) to lymphocytes inhibited cellular processing of gp160 to gp120, and decreased HIV-1 virion gp120. Since gp120 is important in syncytia formation and in HIV-1 infectivity, these findings may explain protection of SV(AT)-transduced cells from both events. Inhibition of gp160 processing is known to generate viral particles unable to activate the necessary fusion between the viral particle and the plasma membrane of the target cell. 19 Interestingly, for some viruses, a direct correlation between the efficiency of virus proprotein cleavage by cellular endoproteases and virulence can be drawn. 37, 38 Native a 1 AT may provide an alternative to the peptides mimicking the cleavage region of gp160. Despite their efficiency, these latter inhibitors have had toxic side effects, limiting their use as antiviral agents. 39 In AIDS therapy, the rate of drug-induced mutation of HIV-1 is still a major problem.
40-42 HIV-1 proteins evolve quickly in response to measures intended to inhibit their activities. However, the virus requires certain cellular functions in order to generate infectious progeny. These cellular functions are unlikely to be rescued by virus mutation and thus may be important targets for anti-HIV therapeutics. Our results showed that a 1 AT inhibits HIV-1 glycoprotein processing, a process that is known to require the activity of cellular endoproteases. Thus, a treatment based on using native a 1 AT to inhibit HIV-1 replication may be useful despite the virus' ability to mutate.
We tested whether the protease inhibitor a 1 AT could also interfere with HIV-1 protein processing by blocking HIV-1 p55
Gag proteolytic maturation elicited by the retroviral aspartyl protease HIV-1 PR. HIV-1 PR is encoded within the pol gene of the virus and is responsible for maturation of the nascent viral particle. The HIV-1 viral gag and gag/pol are expressed as polyprotein. Excision of individual enzymes and structural proteins is felt to be performed by the aspartyl protease, HIV-1 PR, and largely occurs in budding virions. 21 Unexpectedly, Western blot analyses showed that SV(AT) inhibited processing of p55
Gag in SupT1 cells and in primary human lymphocytes; high levels of uncleaved p55
Gag protein accumulated within cells and were detected in virus particle progeny recovered from these cells after transduction with SV(AT).
These results strongly suggest that a 1 AT inhibits activity of HIV-1 PR, an aspartyl protease. The mechanism(s) by which a 1 AT inhibits HIV-1 PR requires further investigation. Such promiscuity in a 1 AT inhibitory functions has already been reported: a 1 AT was shown to be a competitive inhibitor of renin, 43 an enzyme belonging to the aspartyl protease family, and the observed a 1 AT-related decreases in HIV-1 PR activity might represent comparable cross-reactivity. Other possibilities exist as well. For example, a cellular serine protease may be necessary for the activation of HIV-1 PR. Alternatively, the virus assembly and colocalization of HIV-1 PR protein and p55
Gag may also involve one or more as yet undefined serine protease activities. These possibilities are not mutually exclusive, and are being investigated.
Crucial activities in which HIV relies on a cellular enzyme function may represent points in the virus replicative cycle that are less susceptible to being circumvented by HIV mutations. They may therefore point to vulnerabilities in HIV replication that could be attractive targets for anti-HIV therapeutics.
The use of recombinant replication-deficient SV40-derived vectors allows stable expression of transgene with high efficiency and without selection in cell lines, primary cell cultures, and in vivo; rSV40s stably integrate into the host genome and are effective vehicles whether or not target cells are dividing. [24] [25] [26] Furthermore, rSV40s do not elicit cellular or humoral immune responses in animals. 27 The fact that a 1 AT occurs naturally in human blood makes immune responses against a 1 AT highly unlikely. The ultimate test for this inhibitor will be its transfer in CD34+ hematopoietic, to allow continuous repopulation of a patient's immune system with such genetically altered cells. For such an approach to be practicable, a conditional promoter that is HIV-1-specific, such as the HIV-1 LTR, should regulate expression of a 1 AT. We have used this promoter efficiently to deliver conditional expression of other transgenes, 43 and are currently devising such a construct to deliver a 1 AT.
In conclusion, delivering a 1 AT to human lymphocytic cell lines or primary human lymphocytes using SV(AT) as a vector strongly inhibits HIV-1 replication and spread. The likely mechanism for this effect is direct Inhibiting HIV-1 proprotein processing P Cordelier et al inhibition of cellular serine proteases that process gp160. In addition, the activity of HIV-1 PR, an aspartyl protease, that is principally active within budding virions, is also inhibited. a 1 AT delivered by rSV40 may therefore represent a novel and promising gene therapeutic approach, both to interfere with HIV-1 replication, and to study the involvement of serine proteases in HIV-1 replication.
Materials and methods

Plasmids and viral expression constructs
The molecular clone of HIV-1 used in these studies was pNL . This strain was obtained from the NIH AIDS Reagent Repository and was passaged and titered according to standard techniques. HIV-1 NL4-3 is a Ttropic viral strain with highly cytopathic effects.
Construction of recombinant SV40 derivative viruses (rSV40) for gene transfer has been described previously. 24 The construct pT7ma 1 AT, containing a modified a 1 AT cDNA, has been described previously, as has SV(AT), the rSV40 vector derived from it. 44 Briefly, the 5.24 kb SV40 genome (kind gift of Dr Janet Butel, Baylor College of Medicine) was modified by excising the genes for large T antigen (Tag) and small T antigen (tag), without disturbing the SV40 early promoter and the SV40 polyadenylation signal. The late viral genes, VP1, VP2 and VP3, which encode capsid proteins, also remain. The human a 1 AT cDNA was inserted downstream of the SV40 early promoter, driven by the cytomegalovirus immediate early promoter (CMV-IEP). Control viruses for these studies have been reported: SV(HBS) and SV(BUGT), which respectively carry the cDNA for hepatitis B surface antigen (HBsAg) and human bilirubin-UDPglucuronosyl-transferase. 44, 45 Production of rSV40 derivative virus
The techniques used to generate rSV40 viruses from such plasmids as pT7ma 1 AT have been described. 24 Briefly, the virus genome was excised from the carrier plasmid and purified by agarose gel electrophoresis. It was then recircularized and transfected into COS-7 cells, the packaging cell line used for these studies. No helper virus was used: COS-7 cells supply the necessary Tag in trans. Virus stocks were prepared as cell lysate then purified as described elsewhere. 24 Resulting viruses are replication incompetent. Virus stock is titered by in situ PCR as reported. 46 
Cell culture
The COS-7 packaging cell line was maintained in Dulbecco's modified Eagle's medium (DMEM) with 2 mM L-glutamine adjusted to contain 1.5 g/l. sodium bicarbonate, 4.5 g/l glucose, 1.0 mM sodium pyruvate, streptomycin (100 mg/ml), penicillin (200 units/ml), gentamicin (10 mg/ml) and 10% (vol/vol) fetal calf serum. The same culture conditions were used for 293T cells. SupT1 CD4-positive human T-lymphocyte cell line susceptible to HIV-1 infection was grown in RPMI-1640 medium, streptomycin (100 mg/ml), penicillin (200 units/ml), gentamicin (10 mg/ml) and 10% (vol/ vol) fetal bovine serum (complete RPMI). The human hepatocellular carcinoma cell line HepG2 was grown in Dulbecco's modified Eagle's minimum essential medium with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino acids, 1.0 mM sodium pyruvate, streptomycin (100 mg/ml), penicillin (200 units/ml), gentamicin (10 mg/ml) and 10% (vol/vol) fetal bovine serum. All the cells were grown at 371C in humidified incubator with 5% CO 2 .
Source and preparation of peripheral blood lymphocytes
Venous blood from HIV-1-negative individuals without identifiers was obtained through the Thomas Jefferson University blood donor center. Peripheral blood mononuclear cells (PBMC) were prepared by Histopaque-1077 density separation (Sigma). The isolated PBMC were cultured overnight in complete RPMI. Cell preparations enriched in PBL were obtained after separation from plastic adherent mononuclear cells and macrophages. For simplicity, these adherent cell-depleted PBMC preparations are referred to as PBL. PBL were maintained in complete RPMI in the presence of natural human purified interleukin II (20 units/ml, GIBCO) at 371C in a humidified CO 2 incubator.
Transduction
For transduction with SV40-derived virus, SupT1 cells and PBL were treated for 24 h at an MOI of 10. This treatment was repeated twice, but at an MOI of 3, on sequential days. No selection was used. The rSV40-treated cells were then cultured for 5 days before further manipulation. For the purposes of transduction, PBL were cultured without added IL-2. Following transduction, PBL were cultured with IL-2 as described.
Detection of a 1 AT by Northern blot
Total RNA from parental cells alone and cells expressing a 1 AT or HBsAg was extracted using RNAeasy s Mini Kit (Qiagen). mRNAs were detected by Northern hybridization analysis as previously described employing a human a1AT cDNA probe. Samples of 15 mg of total RNA were electrophoresed in a 1% agarose/formaldehyde gel, transferred on a nylon filter (Nytran Super Charge, Schleicher and Schuell), UV cross linked with a Stratalinker oven (Stratagene), and baked for 2 h at 801C. The filters were prehybridized in 50% formamide, 5 Â SSPE, 20 mg/ml denaturated salmon sperm DNA, 5 Â Denhardt's, 0.1% SDS at 421C for 8 h. The filters were subsequently hybridized under the same conditions with a a1AT cDNA probe labeled with a- 
HIV-1 viral stocks
293T cells were transfected using calcium phosphate (Promega). 1 Â 10 6 293T cells were plated in 10 cm dishes, transfected with 10 mg of pNL 4-3 DNA, then incubated in DMEM containing streptomycin (100 mg/ ml), penicillin (200 units/ml), gentamicin (10 mg/ml) and 10% (vol/vol) fetal calf serum for 7 h. The medium was then removed and replaced with fresh DMEM containing 
HIV-1 infectious assays
The HIV-1-susceptible T cells (SupT1,PBL) that expressed the a 1 AT, HBsAg or BUGT proteins were maintained in complete RPMI for 5 days before HIV-1 challenge four hours before infection of the cells with HIV-1 NL4-3 , 1 Â 10 6 mock-transduced cells and cells expressing a 1 AT, HBsAg or BUGT were plated in 1 ml of medium per well in a 12-well plate. Cells were infected with various TCID 50 of cell-free HIV-1 NL4-3 overnight. The cells were washed with prewarmed, serum-free medium and maintained in growth medium. Every 3 days, half of the supernatant was changed and aliquoted for HIV-1 p24 analyses. Every 3 days, cells were split in a 1:2 ratio to maintain a cell density of approximately 1 x 10 6 /ml. The HIV-1 p24 antigen levels in supernatant were determined by ELISA. The infectious doses of HIV-1 used in these experiments are expressed as TCID 50 per 1 x 10 6 cells per ml of culture.
Protein isolation from virions
5 Â 10 6 SupT1 cells and PBL, either mock-transduced or expressing a 1 AT, HBsAg or BUGT proteins, were infected with 10 000 and 40 000 TCID 50 of HIV-1 NL4-3 , respectively. The cells were washed with prewarmed, serum-free medium and maintained in complete medium. Cell-free culture supernatants (5 ml) were harvested at day 7 post infection, and subjected to ultracentrifugation at 40 000 g for 120 min at 41C. Virus pellets were resuspended and lysed on ice in 1 ml of lysis buffer (50 mM Tris, pH 7.4/150 mM NaCl/1% Nonidet P-40/1% sodium deoxycholate/1 Â protease inhibitor mix (Sigma)/0.5 mM sodium orthovanadate/0.02% sodium azide) for 15 min. The protein suspension was subsequently concentrated using centricon centrifugal filter devices (Millipore). Centricon YM-10 (cut-off value 10 kDa) were used for p55 GAG Western studies, whereas YM-50 (cut-off value 50 kDa) were used for gp120 Western studies.
Immunoprecipitation of a1AT
5 Â 10 6 mock-transduced SupT1 and cells expressing a 1 AT proteins were lysed on ice in 500 ml of lysis buffer (50 mM Tris, pH 7.4/150 mM. NaCl/1% Nonidet P-40/1% Sodium deoxycholate/1 Â protease inhibitor mix (Sigma)/0.5 mM sodium orthovanadate/ 0.02% sodium azide) for 5 min. The protein suspension was transferred to a microfuge tube and was spun for 20 min at 15 000 Â g to remove cell debris. 500 mg of total cell proteins was incubated with 1/10 dilution of polyclonal anti-a 1 AT antibody (Sigma) overnight at 41C under agitation. Protein A sepharose was then added for 3 h at 41C under agitation. Immune complexes were extensively washed with lysis buffer, then boiled for 5 min. Proteins were separated by 4-20% Ready SDS/PAGE (Bio-Rad) and transferred to a PVDF-Plus membrane (Osmonics, Minnetonka, MN, USA). After room temperature blocking for 1 hour (PBS (pH 7.4)/0.1% Tween-20 containing 5% milk ), blots were incubated overnight at 41C with a polyclonal anti-a 1 AT antibody (Sigma) (1:200) . Secondary antibodies goat anti-rabbit (Pierce) horseradish peroxidase-conjugated antibodies (1:10 000) were added, and blots were incubated for 1 h at room temperature. Each antibody incubation was followed by four washes in PBS (pH 7.4)/0.1% Tween-20. Chemiluminescence (ECL Plus, Amersham) was performed as directed by the manufacturer.
Immunostaining for a 1 AT expression 50 x 10 3 SV(HBS)-transduced SupT1 and cells expressing a 1 AT proteins are transferred 2 weeks post-transduction to four-chambered glass slides. Cells are fixed with PBS/ 4% PFA pH 7.4 at room temperature for 20 min, permeabilized using PBS/0.1% NP40 for 10 min at room temperature, and blocked overnight in normal donkey serum at 41C. Slides are treated for 1 h at 371C with a 1:200 dilution of polyclonal goat anti-a 1 AT (Sigma) for 1 h at 371C. After extensive washes with PBS, cells are incubated with a 1:1000 dilution of Alexa Fluir 546 labeled donkey anti-goat IgG (Molecular Probe) for 1 h at 371C. After extensive washes in PBS, cells are mounted and analyzed by epifluorescence microscopy.
Western blot analysis
x 10
6 mock-transduced SupT1 and PBL, and cells expressing a 1 AT, HBsAg or BUGT proteins, were treated for 1 week with 4000 and 10 000 TCID 50 of HIV-1 NL4-3 , respectively. After one wash in PBS, cells were lysed on ice in 500 ml of lysis buffer (50 mM Tris, pH 7.4/150 mM NaCl/1% Nonidet P-40/1% sodium deoxycholate/1 Â protease inhibitor mix (Sigma)/0.5 mM sodium orthovanadate/0.02% sodium azide) for 5 min. The protein suspension was transferred to a microfuge tube and was spun for 5 min at 10 000 g to remove cell debris. The protein suspension was subsequently concentrated using centricon centrifugal filter devices (Millipore). Centricon YM-10 (cut-off value 10 kDa) were used for p55 GAG Western studies, whereas YM-50 (cut-off value 50 kDa) were used for gp120 Western studies. For gp120 Western blots, proteins were separated by 5% TB PAGE SDS-free (Bio-Rad). For p55
Gag Western blots, proteins were separated by 4-20% Ready SDS/PAGE (Bio-Rad) and transferred to a PVDF-Plus membrane (Osmonics, Minnetonka, MN,USA). After overnight blocking (PBS (pH 7.4)/0.1% Tween-20 containing 5% milk), blots were incubated with mouse anti-gp120 ID6 antibody (ARRRP # 2343) (1:1000) or sheep anti-p24 antibody (ARRRP #287) (1:500) in PBS (pH 7.4)/0.1% Tween-20 containing 1% milk for 3 h at room temperature. Secondary antibodies of rabbit anti-mouse or goat anti-sheep (Pierce) horseradish peroxidase-conjugated antibodies (1:10 000) were added, and blots were incubated for 1 h at room temperature. Each antibody incubation was followed by four washes in PBS (pH 7.4)/0.1% Tween-20. Chemiluminescence (ECL Plus, Amersham) was performed as directed by the manufacturer. It should be emphasized that to facilitate clear resolution of gp160 and gp120 bands, smaller amounts of total proteins from SV(HBS)-transduced, or later SV(BUGT)-transduced cells and viral progeny were loaded per lane than from SV(AT)-transduced cells and viral progeny. To test for an equal protein loading of the various lanes, p55
Gag Inhibiting HIV-1 proprotein processing P Cordelier et al Western blots were stripped and incubated with goat anti-human Lamin A (1:500) (Santa Cruz Biotechnology).
